Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 317

The DOI matches its Crossref record.

Bladder Cancer

Open access
Clark, Peter E., Agarwal, Neeraj, Biagioli, Matthew C., Eisenberger, Mario A., Greenberg, Richard E., Herr, Harry W., Inman, Brant A., Kuban, Deborah A., Kuzel, Timothy M., Lele, Subodh M., Michalski, Jeff, Pagliaro, Lance C., Pal, Sumanta K., Patterson, Anthony, Plimack, Elizabeth R., Pohar, Kamal S., Porter, Michael P., Richie, Jerome P., Sexton, Wade J., Shipley, William U., Small, Eric J., Spiess, Philippe E., Trump, Donald L., Wile, Geoffrey, Wilson, Timothy G., Dwyer, Mary, Ho, Maria·2013·Journal of the National Comprehensive Cancer Network

Abstract

Urothelial tumors represent a spectrum of diseases with a range of prognosis. After a diagnosis is established at any point within the urothelial tract, the patient remains at risk for developing a new lesion at a different or the same location and at a similar or more advanced stage. Continued monitoring for recurrence is an essential part of management, because most recurrences are superficial and can be managed endoscopically. Within each category of disease, more refined methods to determine prognosis and guide management, based on molecular staging, are under development with the goal of optimizing the individual patient's likelihood of cure and chance for organ preservation. For patients with more extensive disease, newer treatments typically involve combined-modality approaches, using recently developed surgical procedures, or three-dimensional treatment planning for more precise delivery of radiation therapy. Although these are not appropriate in all cases, they do offer the promise of an improved quality of life and prolonged survival. Finally, within the category of metastatic disease, a number of new agents have been identified that appear to be superior to those currently considered to be standard therapies. Experts believe, therefore, that the treatment of urothelial tumors will evolve rapidly over the next few years, with improved outcomes for patients at all stages of disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.6004/jnccn.2013.0059

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 317

Metadata

Authors
Clark, P. E., Agarwal, N., Biagioli, M. C., Eisenberger, M. A., Greenberg, R. E., Herr, H. W., Inman, B. A., Kuban, D. A., Kuzel, T. M., Lele, S. M., Michalski, J., Pagliaro, L. C., Pal, S. K., Patterson, A., Plimack, E. R., Pohar, K. S., Porter, M. P., Richie, J. P., Sexton, W. J., Shipley, W. U., Small, E. J., Spiess, P. E., Trump, D. L., Wile, G., Wilson, T. G., Dwyer, M., & Ho, M.
Venue
Journal of the National Comprehensive Cancer Network
Published
2013-04
Volume
11
Issue
4
Pages
446-475
ISSN
  • 1540-1405 (ISSN-L)
  • 1540-1413
OpenAlex
W169084277
Cited by
317
References
0
FWCI
42.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bladder Cancer. https://app.cochat.ai/papers/10.6004/jnccn.2013.0059
The paper
Clark, P. E., Agarwal, N., Biagioli, M. C., Eisenberger, M. A., Greenberg, R. E., Herr, H. W., Inman, B. A., Kuban, D. A., Kuzel, T. M., Lele, S. M., Michalski, J., Pagliaro, L. C., Pal, S. K., Patterson, A., Plimack, E. R., Pohar, K. S., Porter, M. P., Richie, J. P., Sexton, W. J., . . . Ho, M. (2013). Bladder Cancer. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2013.0059

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.